Fabrication and TXL Anti-cancer Drug Delivery of Magnetic Mesoporous Silica Nanoparticles

Magnetic Fe3O4 @ SiO2 mesoporous silica nanoparticles(MSNs) were synthesized with Fe3O4 nanoparticles as crystal core, cetyltrimethylammium bromide (CTAB) as structural directional agent through the hydrolysis of tetraethoxysilane(TEOS) and self-assembly procedure under the basic conditions. The synthesized MSNs were characterized via the XRD, FTIR, TEM and N-2 adsorptiom-desorption. The results show that these MSNs have high sepcific surface area of 932 cm(2)/g, particles size of 150 nm and typical hexagonal packing mesoporous structure. Simultaneously, all Fe3O4 nanoparticles are perfectly embedded in silica bulk. As a TXL carrier, Fe3O4 @ SiO2 exhibits good adsorption with the maximum adsorption capacity of 80 mg/g and TXL-Fe3O4@ SiO2 has a more than 120 h sustained release for TXL with accumulative quantity of 30 mg/g. While the release behaviour is controlled by various pH values. Higher the pH is, larger the accumulative release is. Experiments of cytotoxicity on HeLa cells indicate that the Fe3O4 @ SiO2 particles exhibit excellent biocompatibility. TXL-Fe3O4@ SiO2 shows significant inhibition effect on HeLa cells than bare TXL under the same drug concentration.